Meet the Team

telegraph hill partners Deval Lashkari

Deval

Lashkari, Ph.D.

Senior Partner

Deval is a co-founder of THP and has worked in the life sciences area developing and commercializing novel technologies for over 25 years. He gained experience as an entrepreneur and through senior management positions in a number of life science companies. He was a founding Research Director at Synteni, which was acquired by Incyte Genomics, where he became Director of Product Development. He also worked with Operon Technologies (acquired by Qiagen), leading product development and commercial strategies. Deval has represented THP on the boards of AcroMetrix (acquired by Life Technologies), Agena Bioscience (acquired by Mesa Laboratories), Akoya Biosciences (NASDAQ:AKYA), Althea Technologies (acquired by Ajinomoto), Applied Precision (acquired by GE), Argonaut Manufacturing Services, Aurora Discovery (acquired by NEXUS Biosystems), Asuragen (acquired by Bio-Techne), Cell Microsystems, Dynex, EditCo, Excellos, NEXUS Biosystems (acquired by Brooks Automation), Nimble Therapeutics, n6 Tec, Panome Bio, Precision NanoSystems (acquired by Danaher), RareCyte, Sage Labs (acquired by Horizon Discovery), and SwitchGear Genomics (acquired by Active Motif). He has been an observer on the boards of Dharmacon (acquired by Fisher Scientific), Carterra and Mosaic Biosciences. Deval received a BA with highest honors from the University of California, Berkeley and a PhD from Stanford University and currently serves as President of the Stanford Medical School Alumni Board of Governors.